Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First)
5 days ago
- #quizartinib
- #AML
- #patient-reported outcomes
- QuANTUM-First is a phase 3 trial evaluating quizartinib vs. placebo in newly diagnosed FLT3-ITD-positive AML patients.
- Patient-reported outcomes (PROs) were assessed using the EORTC 30-item Core Quality of Life Questionnaire.
- No substantial differences in health-related quality of life (HRQoL) were found between quizartinib and placebo groups.
- Quizartinib plus standard chemotherapy prolonged overall survival without negatively impacting PROs.
- Future research is needed to assess the generalizability of these PRO results in real-world settings.